Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats

Published

First veterinary commercial sale of the SRT-100 outside the U.S.

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S.

Veterinary Specialist Referral Center Knowledge Farm was established in 2007 at Beit Berl College to provide imaging (ultrasound, CT and radiographs), general orthopedic soft tissue services and veterinary oncology services to general veterinary practitioners and their clients. Soon thereafter, an Emergency and Critical Care Center was established, which operates 24 hours a day. Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel with more than 20 board-certified specialists and emergency physicians, and more than 30 qualified veterinary technicians and support staff.

Previously Colorado State University (CSU) College of Veterinary Medicine and Biomedical Studies acquired two SRT-100 systems: one to treat companion animals in its small animal hospital and the other to treat and to conduct studies primarily in equine ophthalmic tumors at the Johnson Family Equine Hospital in Fort Collins. CSU in recent weeks presented data showing that SRT can be used as a novel and safe treatment modality for equine eyelid squamous cell carcinoma.

“Whether for treating small animals like cats, dogs, turtles and birds, or large ones like horses, our technology is a valuable addition to leading veterinary practices worldwide. With great technology in the hands of great doctors, the benefits of our SRT-100 System in this vertical are clear. Our advanced technology helps keep skilled practitioners at the top of their field, while their patients benefit from a non-invasive option with no pain, no anesthesia, fast recovery and no fear,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.

“The veterinary channel represents a large and exciting incremental growth opportunity for Sensus, as thought-leading institutions with tremendous knowledge and experience like CSU and now Chavat Da’at demonstrate the utility and versatility of our products. These leaders are exploring and expanding the veterinary indications for radiotherapy, while making treatments increasingly available and affordable to many more pet owners,” he added.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to maintain profitability; our ability to sell the number of SRT units we anticipate for the balance of 2024; the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the performance of the Company’s information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

To date, we do not expect that the Middle East conflict, the Russian invasion of Ukraine and global geopolitical uncertainty have had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.

Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

Contact: LHA Investor Relations Kim Sutton Golodetz212-838-3777kgolodetz@lhai.com

# # #

Primary Logo

Source: Sensus Healthcare, Inc.

In This Story

SRTS